ABSTRACT
The molecular subtype classification of endometrial carcinomas has conceptually changed our approach to this disease. However, open questions remain about how to integrate certain histotype diagnoses with the molecular subtype. We report 2 cases with morphologic suspicion for endometrial carcinosarcoma, that still fell short of the essential criteria for diagnosing carcinosarcoma. On subsequent molecular testing pathogenic POLE mutations were detected and a descriptive diagnosis of endometrial endometrioid carcinomas, low-grade with a homologous sarcoma component was rendered. This challenges the existence of POLE-mutated "carcinosarcoma."
ABSTRACT
BACKGROUND: Pediatric fibroblastic/myofibroblastic tumors (PFMTs) can be challenging to definitively classify. Large case series or diagnostic updates have not been recently published despite identification of molecular alterations that could improve diagnostic accuracy. Our review of the literature found that over two-thirds of the more than 30 types of PFMTs harbor recurrent molecular alterations. We performed an institutional review of PFMTs to highlight limitations of a predominantly morphological classification, and evaluated the utility of a next-generation sequencing assay to aid diagnosis. METHODS: PFMTs identified over a period of 12 years were reviewed, categorized per the new WHO classification, and tested using the Oncomine Childhood Cancer Research Assay. RESULTS: Eighty-seven specimens from 58 patients were reviewed; 50 were chosen for molecular analysis, 16 (32%) lacking definitive classification. We identified alterations, some novel, in 33% of assayed cases. Expected alterations were identified for most known diagnoses and mutations were identified in 6 of 16 tumors (38%) that were initially unclassified. CONCLUSION: We confirmed a significant subset of PFMTs remain difficult to classify using current criteria, and that a combined DNA/RNA assay can identify alterations in many of these cases, improving diagnostic certainty and suggesting a clinical utility for challenging cases.
Subject(s)
Biomarkers, Tumor/genetics , Fibroma/genetics , Granuloma, Plasma Cell/genetics , High-Throughput Nucleotide Sequencing , Myofibroma/genetics , Sarcoma/genetics , Soft Tissue Neoplasms/genetics , Adolescent , Child , Child, Preschool , Female , Fibroma/classification , Fibroma/diagnosis , Fibroma/pathology , Granuloma, Plasma Cell/classification , Granuloma, Plasma Cell/diagnosis , Granuloma, Plasma Cell/pathology , Humans , Infant , Infant, Newborn , Male , Mutation , Myofibroma/classification , Myofibroma/diagnosis , Myofibroma/pathology , Oncogene Proteins, Fusion/genetics , Retrospective Studies , Sarcoma/classification , Sarcoma/diagnosis , Sarcoma/pathology , Soft Tissue Neoplasms/classification , Soft Tissue Neoplasms/diagnosis , Soft Tissue Neoplasms/pathology , World Health OrganizationABSTRACT
Two primary patterns of placental calcification have been described, each with distinctive pathophysiology and clinical relevance. We report a novel pattern of diffuse subamniotic calcification. It occurred in a 25-week placenta involved by recurrent chronic histiocytic intervillositis (CHI) associated with severe intrauterine growth restriction (IUGR) and intrauterine fetal demise (IUFD). This was the mother's third stillbirth related to CHI, despite treatment with intravenous immunoglobulin (IVIG), prednisone, low-molecular-weight heparin, and acetylsalicylic acid (ASA). On placental examination, the majority of the fetal surface was calcified. This variably formed a continuous band or dispersed calcium microparticles. Electron microscopy demonstrated associated electron dense deposits highly suggestive of immune complex deposition. CHI explains recurrent IUGR and stillbirth, but has not been associated with calcification or immune complex deposition. We hypothesize IVIG therapy may have caused immune complex deposition and subsequent dystrophic calcification, supported by its rare association with immune complex deposition disorders in the kidney. Identification of additional cases with this pattern of calcification, with additional studies on fresh tissue including immunofluorescence, electron microscopy and mass spectrometry, may aid in elucidating the underlying pathophysiology and clinical significance of this unusual lesion.
Subject(s)
Calcinosis/pathology , Placenta Diseases/pathology , Placenta/pathology , Stillbirth , Adult , Calcinosis/diagnosis , Calcinosis/physiopathology , Female , Fetal Growth Retardation/etiology , Humans , Placenta Diseases/diagnosis , Placenta Diseases/physiopathology , PregnancyABSTRACT
Eosinophilic/T-cell chorionic vasculitis (ETCV) is an idiopathic placental lesion characterized by chorionic vasculitis composed predominantly of eosinophils and CD3+ T lymphocytes. It usually presents as a unifocal lesion, but a subset have multifocal involvement. We report 4 Di-Di and 2 Di-Mo twins sharing fused placental discs with discordant circulatory involvement by multifocal ETCV. The findings are difficult to explain by sampling alone. The limitation of ETCV to 1 fetus's vascular territory in monozygotic twin pregnancies is difficult to explain but could provide insights into the fetal immune system and the etiology of ETCV.
Subject(s)
Chorion/pathology , Eosinophilia/pathology , Placenta Diseases/pathology , Placenta/pathology , T-Lymphocytes/metabolism , Twins, Monozygotic , Vasculitis/pathology , Biomarkers/metabolism , Chorion/immunology , Eosinophilia/immunology , Female , Humans , Infant, Newborn , Male , Placenta/immunology , Placenta Diseases/immunology , Pregnancy , Pregnancy, Twin , Vasculitis/immunologyABSTRACT
Context: Two-thirds of metastatic differentiated thyroid cancer (DTC) patients have radioiodine (RAI)-resistant disease, resulting in poor prognosis and high mortality. For rare NTRK and RET fusion-positive metastatic, RAI-resistant thyroid cancers, variable success of re-induction of RAI avidity during treatment with NTRK or RET inhibitors has been reported. Case presentation and results: We report two cases with RAI-resistant lung metastases treated with larotrectinib: an 83-year-old male presenting with an ETV6::NTRK3 fusion-positive tumor with the TERT promoter mutation c.-124C>T, and a 31-year-old female presenting with a TPR::NTRK1 fusion-positive tumor (and negative for TERT promoter mutation). Post larotrectinib treatment, diagnostic I-123 whole body scan revealed unsuccessful RAI-uptake re-induction in the TERT-positive tumor, with a thyroid differentiation score (TDS) of -0.287. In contrast, the TERT-negative tumor exhibited successful I-131 reuptake with a TDS of -0.060. Conclusion: As observed for RAI-resistance associated with concurrent TERT and BRAF mutations, the co-occurrence of TERT mutations and NTRK fusions may also contribute to re-sensitization failure.
Subject(s)
Iodine Radioisotopes , Thyroid Neoplasms , Humans , Iodine Radioisotopes/therapeutic use , Thyroid Neoplasms/genetics , Thyroid Neoplasms/pathology , Thyroid Neoplasms/radiotherapy , Male , Female , Adult , Aged, 80 and over , Pyrimidines/therapeutic use , Oncogene Proteins, Fusion/genetics , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Lung Neoplasms/radiotherapy , Lung Neoplasms/secondary , Pyrazoles/therapeutic use , Receptor, trkA/genetics , Telomerase/genetics , Receptor, trkC/genetics , Receptor, trkC/metabolism , Repressor Proteins/genetics , Proto-Oncogene Proteins c-ets/genetics , Mutation , ETS Translocation Variant 6 ProteinABSTRACT
Genome-based testing in oncology is a rapidly expanding area of health care that is the basis of the emerging area of precision medicine. The efficient and considered adoption of novel genomic medicine testing is hampered in Canada by the fragmented nature of health care oversight as well as by lack of clear and transparent processes to support rapid evaluation, assessment, and implementation of genomic tests. This article provides an overview of some key barriers and proposes approaches to addressing these challenges as a potential pathway to developing a national approach to genomic medicine in oncology.
Subject(s)
Genomic Medicine , Technology Assessment, Biomedical , Humans , Canada , Medical Oncology , GenomicsABSTRACT
INTRODUCTION: Recurrence risk of villitis of unknown etiology (VUE) remains uncertain because of few studies and their methodologic limitations. We calculated recurrence risk in a large population of deliveries after minimizing important biases and compared it to others via systematic review and meta-analysis. METHODS: Over 11 years of placenta pathology reports on singleton deliveries were retrieved and searched for 'villitis' or 'VUE'. Cases of acute villitis and chronic villitis from infections were eliminated via pathologist review. Reports were merged to data containing gestational age, parity and gravida. Recurrence risk of VUE per patient, per parity and per gravida was determined among patients with ≥2 placentas examined for deliveries ≥20 weeks gestation. Results were compared to those from articles and their references identified by a MEDLINE® search. Recurrence risks among methodologically similar studies were pooled using a random effects model. RESULTS: Among 29 124 placenta pathology reports from 27 087 patients, there were 2423 cases of VUE among 2382 patients, of which 153 had ≥2 placentas examined. There were 41 recurrent cases of VUE for a recurrence risk of 27% per patient, 22% per parity, and 19% per gravida. We identified 64 articles, of which 4 were retained. One examined all placentas from all births over a â¼3-year period, finding a recurrence risk of 27%. The remaining 3 studies, along with our own, used indications for placental examination and had a pooled recurrence risk of 30% (95% Confidence Interval: 0.21-0.41). DISCUSSION: In our study, which is the largest, most comprehensive, and methodologically robust to date, VUE recurrence risk was â¼30%.
Subject(s)
Chorioamnionitis , Placenta Diseases , Chorioamnionitis/pathology , Chorionic Villi/pathology , Female , Humans , Placenta/pathology , Placenta Diseases/epidemiology , Placenta Diseases/etiology , Placenta Diseases/pathology , Pregnancy , Retrospective StudiesABSTRACT
Neuroblastoma is the most common cancer in infants younger than 12 months of age, occurring with an incidence of 1 in 100,000 children. The clinical outcome of neuroblastoma ranges from spontaneous regression to treatment-resistant progression and/or metastasis, and accounts for 8-10% of childhood cancer deaths. Segmental chromosomal aberrations, as well as MYCN and ALK amplification, are among factors contributing to an unfavorable genomic profile and high-risk disease classification. Here, we describe a 5-year-old male who presented with a large right renal neuroblastoma tumor having lung and liver metastases. Fluorescence in situ hybridization analysis indicated the presence of >20 copies of the 5' region of the ALK gene in 26% of cells examined. Subsequent copy number assessment did not confirm ALK amplification, but revealed a gain of exons 2-5 of ALK, consistent with increased copy number for the 5' region of the ALK gene. Subsequent array analysis showed the presence of other unfavorable prognostic genomic features, including segmental gain of the 17q region and amplification of the long arm of chromosome 12 harboring CDK4 and MDM2, both reported to be poor prognostic indicators in patients with atypical clinical features in neuroblastoma. Taken together, this report illustrates the importance of careful interpretation of aberrant FISH findings and subsequent use of orthogonal methods to clarify the presence of genomic alterations to successfully determine potential treatment targets.
ABSTRACT
We report varicella-zoster virus (VZV) gastritis in a 70-year-old woman postchemotherapy for lymphoma, presenting with abdominal pain, vomiting, and delirium without rash. A gastric biopsy demonstrated viral inclusions but posed a diagnostic challenge as immunohistochemistry for cytomegalovirus and herpes simplex virus were negative, and VZV immunohistochemistry was not available. The patient developed a vesicular rash 7 days after her symptoms began. Molecular testing of the gastric biopsy and a skin swab both confirmed VZV infection. She also had probable involvement of her liver and pancreas based on imaging and serum chemistry, and possible central nervous system involvement. She recovered with appropriate antiviral therapy but later developed a postherpetic neuralgia, and chronic intrahepatic biliary strictures; liver biopsy demonstrated a cholangiopathy of uncertain etiology. A literature review of the pathogenesis, epidemiology and sequelae of VZV infection is included.
Subject(s)
Antineoplastic Agents/therapeutic use , Esophagitis/virology , Gastritis/virology , Herpesvirus 3, Human/pathogenicity , Immunosuppression Therapy/adverse effects , Lymphoma/drug therapy , Neuralgia, Postherpetic/diagnosis , Varicella Zoster Virus Infection/virology , Abdominal Pain/drug therapy , Abdominal Pain/etiology , Aged , Antiviral Agents/therapeutic use , Bile Ducts, Intrahepatic/pathology , Constriction, Pathologic/diagnosis , Constriction, Pathologic/pathology , Cytomegalovirus/isolation & purification , Delirium/drug therapy , Delirium/etiology , Endoscopy, Gastrointestinal , Esophagitis/complications , Esophagitis/drug therapy , Esophagitis/pathology , Exanthema/pathology , Exanthema/virology , Female , Gastric Mucosa/diagnostic imaging , Gastric Mucosa/pathology , Gastric Mucosa/virology , Gastritis/complications , Gastritis/drug therapy , Gastritis/pathology , Herpesvirus 3, Human/isolation & purification , Humans , Immunohistochemistry , Immunosuppression Therapy/methods , Liver/pathology , Lymphoma/diagnostic imaging , Nausea/drug therapy , Nausea/etiology , Neuralgia, Postherpetic/drug therapy , Neuralgia, Postherpetic/virology , Positron Emission Tomography Computed Tomography , Simplexvirus/isolation & purification , Skin/pathology , Skin/virology , Varicella Zoster Virus Infection/complications , Varicella Zoster Virus Infection/drug therapy , Varicella Zoster Virus Infection/pathology , Vomiting/drug therapy , Vomiting/etiologyABSTRACT
Differentiating osteoclast-rich lesions of bone (giant cell tumor of bone [GCTB], chondroblastoma [CBA], and aneurysmal bone cyst [ABC]) can be challenging, especially in small biopsies or fine-needle aspirations. Mutations affecting codons 34 and 36 of either H3 Histone Family Member 3A (H3F3A) and/or 3B (H3F3B) are characteristically seen in GCTB and CBAs. We devised a simple assay to identify these mutations and evaluated its applicability for routine clinical diagnosis. One hundred twenty-four tissue specimens from 108 patients (43 GCTBs, 38 CBAs and 27 ABCs) were collected from the archives of the Calgary Laboratory Services/University of Calgary and Vanderbilt University Medical Center. Histology was reviewed by an expert orthopedic pathologist. A single base extension assay (SNaPshot) is used to interrogate each nucleotide in codons 34 and 36 of H3F3A and codon 36 of H3F3B. Final diagnoses were generated after re-reviewing cases and incorporating molecular findings. Of 43 GCTBs, 38 (88%) had an H3F3A G34W mutation; 35 of 38 CBAs (92%) had a K36M mutation in either H3F3B (N = 31; 82%) or H3F3A (N = 4; 11%); none of 27 ABCs had a tested mutation. Molecular findings changed the histomorphologic diagnosis in 5 cases (3 GCTB changed to ABC, and 2 ABC changed to GCTB). These findings support the diagnostic utility of mutational analysis for this differential diagnosis in certain challenging cases when clinicoradiologic and histomorphologic features are not definitive, particularly for distinguishing cellular ABC versus GCTB with secondary ABC.
Subject(s)
Biomarkers, Tumor/genetics , Bone Cysts, Aneurysmal/genetics , Bone Neoplasms/genetics , Chondroblastoma/genetics , DNA Mutational Analysis , Giant Cell Tumor of Bone/genetics , Histones/genetics , Mutation , Osteoclasts/pathology , Adolescent , Adult , Aged , Alberta , Bone Cysts, Aneurysmal/mortality , Bone Cysts, Aneurysmal/pathology , Bone Cysts, Aneurysmal/therapy , Bone Neoplasms/mortality , Bone Neoplasms/pathology , Bone Neoplasms/therapy , Child , Chondroblastoma/mortality , Chondroblastoma/pathology , Chondroblastoma/therapy , Diagnosis, Differential , Disease-Free Survival , Female , Genetic Predisposition to Disease , Giant Cell Tumor of Bone/mortality , Giant Cell Tumor of Bone/pathology , Giant Cell Tumor of Bone/therapy , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Phenotype , Predictive Value of Tests , Tennessee , Time Factors , Young AdultABSTRACT
Antineutrophil cytoplasmic antibody-associated small-vessel vasculitides cause multiple organ system disease including rapidly progressive glomerulonephritis. Recently, Berden et al (J Am Soc Nephrol. 2010;21:1628-1636) proposed a new histopathologic classification scheme separating renal biopsies into 4 classes: focal, crescentic, mixed, and sclerotic. We validated the prognostic implications of this classification scheme in a retrospective cohort study of 67 individuals with antineutrophil cytoplasmic antibody glomerulonephritis who underwent kidney biopsy in Calgary, Alberta, between 2005 and 2010. Their biopsies were rescored according to the classification scheme of Berden et al. Additional tubulointerstitial parameters were also scored. Clinical information including demographics and creatinine values at presentation and 1-year follow-up was retrieved. The mean age was 60 years. Forty-one percent were female. Biopsies were classified as follows: 35% crescentic, 32% mixed, 21% focal, and 11% sclerotic. Ten patients (14%) died within 1 year. Among surviving patients, the overall mean (95% confidence interval) change in estimated glomerular filtration rate (eGFR) at 1 year was 11 (7-15) mL/min per 1.73 m(2), and this change significantly differed (P = .02) between the classes: 19 (11-27) mL/min per 1.73 m(2) with crescentic histology, 11 (1-21) mL/min per 1.73 m(2) with focal, 8 (3-13) mL/min per 1.73 m(2) with mixed, and -4 (-7 to -1) mL/min per 1.73 m(2) with sclerotic. Tubulointerstitial pathology parameters did not predict outcomes. Patients with crescentic class biopsies showed significantly more improvement in eGFR at 1 year compared with the mixed (P = .04) and sclerotic (P = .005) classes. The focal class was associated with the highest eGFR values at presentation and 1 year. These findings validate the prognostic utility of the Berden classification scheme and suggest that it may be generalizable.